|Podcasts|August 23, 2022
SMO, A Model Sustained By Necessity
Author(s)Lisa Henderson, Andy Studna, Senior Editor
Dr. Ian Smith MBE MB ChB.B MedSc(Hons), Founder, Director and Chief Medical Officer of Panthera Biopartners, and Chris Dodd, the company's Chief Commercial Officer, discuss the evolution of the Site Management Organization and Panthera Biopartners, how clinical trials remain mired in underperformance and difficulties, and hybrid trial advancements.
Related Content
Trending on Applied Clinical Trials Online
1
Validity, Reliability, and Regulatory Considerations for Consumer Devices in Clinical Research Data Collection
2
ACT Brief: Real-Time Review Ecosystem Approach, AI Infrastructure Before Tools, and FDA Peptide Compounding Access
3
ACT Brief: ESG as Commercial Selection Factor, Real-Time Monitoring Scale Readiness, and FDA Cancer Trial Eligibility Expansion
4
FDA Finalizes Three Guidances to Broaden Cancer Clinical Trial Eligibility
5